LONDON, August 25, 2011 /PRNewswire/ --
Hikma Pharmaceuticals reports lower-than-expected 3.2% increase
in revenues for the first half but maintains its full-year
outlook.
The international drug developer says that political unrest in
the MENA region disrupted month-on-month sales in some key
countries like Egypt and
Tunisia.
In an interview with financial broadcaster
http://www.cantos.com, Hikma CEO Said
Darwazah says that production is back to normal and that in
spite of difficulties the group managed to grow the business
organically by 3% in the MENA region.
While the group's Multi-Source Injectables division, which was
acquired from Baxter Healthcare last year, was impacted by
transaction delays, Mr Darwazah remains confident the business
"will be breaking even" by the fourth quarter.
Hikma's CEO also makes clear that further acquisitions in
emerging markets are in the pipeline. In the interview he
reiterates full-year guidance of 7% organic growth and 20% overall
business growth.
The interview and transcript are available now on
http://www.cantos.com/company/Hikma%20Pharmaceuticals.
Cantos.com, the online financial broadcaster, features in-depth
interviews, documentaries and webcasts with senior company
executives. If you would like to contact us, please email
amanda.alexander@cantos.com or phone +44-(0)207-936-1372.